Bionano Genomics Inc (BNGO) concluded trading on Wednesday at a closing price of $0.21, with 4.24 million shares of worth about $0.89 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -73.91% during that period and on December 18, 2024 the price saw a loss of about -0.47%. Currently the company’s common shares owned by public are about 101.99M shares, out of which, 101.47M shares are available for trading.
Stock saw a price change of -12.94% in past 5 days and over the past one month there was a price change of -7.89%. Year-to-date (YTD), BNGO shares are showing a performance of -88.89% which decreased to -86.18% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.20 but also hit the highest price of $2.27 during that period. The average intraday trading volume for Bionano Genomics Inc shares is 2.76 million. The stock is currently trading -10.67% below its 20-day simple moving average (SMA20), while that difference is down -24.03% for SMA50 and it goes to -66.56% lower than SMA200.
Bionano Genomics Inc (NASDAQ: BNGO) currently have 101.99M outstanding shares and institutions hold larger chunk of about 5.35% of that.
The stock has a current market capitalization of $21.42M and its 3Y-monthly beta is at 2.27. It has posted earnings per share of -$2.31 in the same period. It has Quick Ratio of 0.99 while making debt-to-equity ratio of 0.46. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BNGO, volatility over the week remained 7.36% while standing at 9.49% over the month.
Stock’s fiscal year EPS is expected to rise by 77.19% while it is estimated to increase by 80.04% in next year.
On January 05, 2023, Scotiabank Initiated their recommendations, while on December 12, 2022, BTIG Research Resumed their ratings for the stock with a price target of $3.50. Stock get an Outperform rating from Oppenheimer on July 18, 2022.
